obesity

News

Lilly sues over 'illegal sales' of obesity drug retatrutide

Eli Lilly has sued six US-based companies it accuses of participating in an illegal black market for experimental weight-loss drug retatrutide.

News

UK is first European country to approve Lilly's Foundayo

Eli Lilly's oral GLP-1 agonist Foundayo has been approved for weight management and type 2 diabetes in the UK, its first European market.

News

Lilly's GLP-1s race away in Q2, though Foundayo falls short

Eli Lilly has posted another record quarter of revenue growth, up 48% to $23bn, with Mounjaro and Zepbound now making up two-thirds of the total.

News

US judge says Novo Nordisk must face lawsuit over CagriSema

A US judge has ruled that Novo Nordisk must face a lawsuit claiming it defrauded investors with misleading statements about a pivotal CagriSema study.

News

Lilly plans Q1 2027 filing for obesity triple retatrutide

Armed with new pivotal trial results, Eli Lilly is preparing to file for approval of its triple-acting weight-loss therapy, retatrutide, next year.

News

Novo's Wegovy pill cleared for weight loss in EU

The EU has approved Novo Nordisk's pill formulation of weight-loss therapy Wegovy, keeping the company a step ahead of arch rival Eli Lilly.

Lilly sues over 'illegal sales' of obesity drug retatrutide

UK is first European country to approve Lilly's Foundayo

Lilly's GLP-1s race away in Q2, though Foundayo falls short

US judge says Novo Nordisk must face lawsuit over CagriSema

Lilly plans Q1 2027 filing for obesity triple retatrutide

Novo's Wegovy pill cleared for weight loss in EU

Click claims FDA okay for first-in-class schizophrenia DTx

Discover a new era of healthcare panel engagement: Grounded ...

obesity

Editor's Picks